Rakuten Securities Inc. Acquires New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Rakuten Securities Inc. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 410 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds have also modified their holdings of the company. PCA Investment Advisory Services Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth $25,000. Tompkins Financial Corp increased its holdings in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares in the last quarter. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences in the 3rd quarter worth $26,000. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth $29,000. Finally, Sanctuary Wealth Management L.L.C. bought a new stake in shares of Gilead Sciences in the 4th quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $66.16 on Friday. The company has a market capitalization of $82.37 billion, a PE ratio of 14.70, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The business’s fifty day moving average is $72.10 and its 200 day moving average is $76.58. Gilead Sciences, Inc. has a fifty-two week low of $65.90 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. During the same quarter last year, the firm posted $1.67 earnings per share. Gilead Sciences’s revenue for the quarter was down 3.7% on a year-over-year basis. Sell-side analysts predict that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.66%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 68.44%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. Royal Bank of Canada cut their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. Oppenheimer cut their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, February 12th. Cantor Fitzgerald cut their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. Finally, UBS Group cut their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $84.71.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.